Discovery MI Gen2 vs OPTIS Mobile Next Imaging
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, GE HealthCare's Discovery MI Gen2, is a diagnostic PET/CT system leveraging AI for high-sensitivity imaging across oncology, neurology, and cardiology. In contrast, Tool B, Abbott Medical's OPTIS Mobile Next Imaging, is an AI-powered intravascular imaging system specifically designed to guide PCI procedures in catheterization laboratories. While both utilize AI in cardiology, their distinct applications in diagnosis versus interventional guidance make them adjacent rather than direct competitors.
Choose Discovery MI Gen2 if…
Choose Discovery MI Gen2 if your institution requires a state-of-the-art, comprehensive diagnostic imaging solution for oncology, neurology, and cardiology. This system is ideal for facilities needing superior image quality, enhanced lesion detectability, and reduced scan times across a broad range of complex cases, leveraging deep-learning AI for precise diagnoses and treatment planning.
View Discovery MI Gen2 →Choose OPTIS Mobile Next Imaging if…
Choose OPTIS Mobile Next Imaging if your cath lab needs an AI-powered, mobile solution for real-time intravascular guidance during Percutaneous Coronary Intervention (PCI) procedures. This system is best suited for cardiologists who require high-resolution Optical Coherence Tomography (OCT) and coronary physiology measurements to optimize stent placement and make informed decisions directly at the patient's bedside.
View OPTIS Mobile Next Imaging →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Discovery MI Gen2 | OPTIS Mobile Next Imaging |
|---|---|---|
| Pricing | Starts at $15,500.00 | Unknown |
| Deployment | On-premise | On-premise (mobile cart system integrated into catheterization laboratories) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Discovery MI Gen2 | OPTIS Mobile Next Imaging |
|---|---|---|
| Company | GE HealthCare | Abbott Medical |
| Description | GE HealthCare's Discovery MI Gen2 is a next-generation digital PET/CT system that leverages deep-learning AI, high sensitivity, and advanced motion correction to deliver superior diagnostic imaging for oncology, neurology, and cardiology. | The OPTISu2122 Mobile Next Imaging System by Abbott Medical is an AI-powered, transportable intravascular imaging system for cath labs, offering high-resolution OCT and coronary physiology measurements to guide PCI procedures with enhanced efficiency and informed decision-making. |
| Categories | Cardiology AI, Neurology AI, Oncology AI | Cardiology AI, Surgical AI |
| Specialties | Nuclear Medicine, Oncology, Radiology | Cardiology |
| Key Features | LightBurst Digital Detector with scalable axial FOV up to 30 cm, High sensitivity (up to 125% increase, 30 cps/kBq), TrueFidelityu2122 deep-learning based image reconstruction, Q.Clear quantitation for accurate SUV measurements and noise reduction, MotionFree digital respiratory motion management solution, Automated patient positioning system (Auto IN), Reduced scan times (up to 50% reduction) and injected dose (up to 50% reduction), Improved small lesion detectability (up to 41% increase) | High-powered processors supporting AI technology (Ultreonu2122 Software) for faster information display and workflow efficiency, Optical Coherence Tomography (OCT) intravascular imaging, Coronary physiology measurements (RFR/FFR) on one platform, Wireless Tableside Controller (TSC) for full control of image acquisition and analysis at the bedside, Seamless and secure integration with cath lab IT systems and DICOM, Transportable system designed for use in multiple cath labs via easy pre-installed connections, Rapid image processing with less than three-second pullback speed for fast image acquisition and interpretation, Simultaneous angio and OCT co-registration for real-time synchronization of images |
Videos
Demos, reviews, and walkthroughs featuring Discovery MI Gen2 and OPTIS Mobile Next Imaging.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
GE HealthCare's Discovery MI Gen2 is a digital PET/CT system designed for superior diagnostic imaging in oncology, neurology, and cardiology. Abbott Medical's OPTIS Mobile Next Imaging System is an AI-powered intravascular imaging system for cath labs, specifically guiding PCI procedures with OCT and coronary physiology measurements.
Discovery MI Gen2 leverages deep-learning AI for TrueFidelityu2122 image reconstruction, improving image quality and small lesion detectability. OPTIS Mobile Next Imaging uses AI (Ultreonu2122 Software) with high-powered processors for faster information display and enhanced workflow efficiency during PCI procedures.
Discovery MI Gen2 provides PET/CT imaging with high sensitivity, Q.Clear quantitation for accurate SUV measurements, and MotionFree digital respiratory motion management. OPTIS Mobile Next Imaging offers Optical Coherence Tomography (OCT) intravascular imaging and coronary physiology measurements like RFR/FFR on a single platform.
Discovery MI Gen2 offers reduced scan times (up to 50%) and injected dose (up to 50%), alongside improved small lesion detectability (up to 41% increase). OPTIS Mobile Next Imaging provides rapid image processing with less than three-second pullback speed for fast image acquisition and interpretation, enhancing workflow efficiency during PCI.